Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489865 | 0.91 | MTOR (0.50) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6683287 | 0.89 | PPARA (0.44) | LMNAKDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL489514 | 0.86 | CACNA1C (0.52) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489360 | 0.86 | ALDH1A1 (0.50) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6689694 | 0.85 | ALDH1A1 (0.51) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489303 | 0.85 | CACNA1C (0.47) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489543 | 0.84 | PPARA (0.51) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL489753 | 0.84 | ADORA3 (0.47) | LMNAMTORKDM4EALDH1A1TSHR | |
| SCHEMBL489551 | 0.83 | ALDH1A1 (0.51) | LMNACACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL17998996 | 0.81 | PPARA (0.50) | LMNACACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470108-B1 | 1,4-DIHYDROPYRIDINE AND PYRIDINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2016-08-24 | — | — | EP | disclosed |
| EP-1542683-B1 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7235570-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2007-06-26 | — | — | US | disclosed |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH (IN) | 2005-07-21 | — | — | US | disclosed |
| US-6852742-B2 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-02-08 | — | — | US | disclosed |
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | Knobbe, Martens, Olson & Bear, LLP | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006110-A1 | To modulate the activity of calcium channels, therapy of cardiovascular disease or neurological disorders, that are associated with calcium channels | RYR2, ORAI1, RYR1 | LMNA 2226/4885CACNA1F 10/4885CACNA1D 5/4885 |
| US-20050159455-A1 | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | RYR1, RYR2, ORAI1 | LMNA 3055/4885CACNA1F 17/4885CACNA1D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.